MedTrace Logo

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT04000009 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2022-04-05

Study results available
· View outcomes & findings →

Summary

To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Conditions

  • Adjunctive Treatment of Major Depressive Disorder

Interventions

DRUG

Pimavanserin

Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-06
Primary Completion
2021-02-22
Completion
2021-02-22
FDA Drug
Yes

Countries

  • United States
  • Finland
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000009 on ClinicalTrials.gov